Yaniv Erlich on building a scalable platform to discover next-gen RNA therapeutics.

Prof. Yaniv Erlich received his bachelor’s degree from Tel-Aviv
University, Israel in 2006 and a PhD from the Watson School of
Biological Sciences at Cold Spring Harbor Laboratory in 2010.
Yaniv Erlich was an Associate Professor of Computer Science at
Columbia University and was a PI at the Whitehead Institute,
MIT. 


 


His research interests are computational human genetics. Yaniv
has been an advisor for multiple companies in the area of
genomics and bioinformatics. He authored over 40 peer-reviewed
scientific studies, including multiple papers in Science, Nature
Genetics, and Nature Methods. He holds five patents and has
experience in both B2C and B2B in the area of genomics.


 


Prof. Yaniv Erlich was the CSO of MyHeritage and currently he is
the CEO of Eleven Therapeutics, a company that he co-founded in
2020. Eleven Therapeutics is a biotech company focused on
development of groundbreaking RNA therapeutics.